Methods for constructing antibiotic resistance free vaccines
The present invention provides Listeria vaccine strains that express a heterologous antigen and a metabolic enzyme, and methods of generating same.
1. A method of inducing an immune response against an antigen-expressing tumor or a n antigen-expressing cancer in a subject, said method comprising the step of administering to the subject a recombinant Listeria strain auxotrophic for D-alanine synthesis, comprising a mutation in a D-alanine racemase gene and in a D-amino acid transferase gene in the chromosome of said recombinant Listeria , wherein said Listeria further comprises a plasmid, wherein the plasmid comprises:
a first nucleic acid sequence encoding a polypeptide, wherein said polypeptide comprises a heterologous antigen, and
a second nucleic acid sequence encoding a D-alanine racemase enzyme, wherein said plasmid does not confer antibiotic resistance upon said recombinant Listeria strain,
whereby said D-alanine racemase gene complements said mutation in said chromosome of said recombinant Listeria , wherein said plasmid is stably maintained in said recombinant Listeria strain in the absence of an antibiotic selection, wherein said first nucleic acid sequence is operably linked to a prokaryotic promoter/regulatory sequence, and wherein said administering induces an immune response against said antigen-expressing tumor or said antigen-expressing cancer in said subject.
2. The method of claim 1 , wherein said polypeptide is a fusion protein comprising said heterologous antigen and an additional polypeptide, wherein said additional polypeptide is a non-hemolytic fragment of a listeriolysin O (LLO) protein, a Proline, Glutamic acid, Serine and Threonine (PEST) amino acid sequence, or an Actin assembly-inducing protein (ActA) protein or a fragment thereof.
3. The method of claim 1 , wherein said second nucleic acid sequence is operably linked to said promoter/regulatory sequence.
4. The method of claim 1 , wherein said heterologous antigen is an HPV E6 or an HPV E7 antigen.
5. The method of claim 1 , wherein said cancer is a cervical cancer.
6. The method of claim 1 , wherein said immune response comprises reducing the size of a HPV antigen-expressing tumor or a HPV antigen-expressing cancer, protecting against recurrence of a HPV antigen-expressing tumor or a HPV antigen-expressing cancer, reducing the growth rate of a HPV antigen-expressing tumor or a HPV antigen-expressing cancer, or inhibiting the growth rate of a HPV antigen-expressing tumor or a HPV antigen-expressing cancer, or any combination thereof.
7. The method of claim 6 , wherein said immune response comprises treating said HPV antigen-expressing tumor or said HPV antigen-expressing cancer.
8. The method of claim 7 , wherein treating said HPV antigen-expressing tumor or said HPV antigen-expressing cancer comprises regression of an established HPV antigen-expressing tumor or an established HPV-expressing cancer.
9. The method of claim 1 , wherein said inducing an immune response comprises inducing a HPV antigen-specific tumor-infiltrating cytotoxic T-cells (CTL).
10. A method of regressing an antigen-expressing tumor or an antigen-expressing cancer in a subject, said method comprising the step of administering to the subject a recombinant Listeria strain auxotrophic for D-alanine synthesis, comprising a mutation in a D-alanine racemase gene and in a D-amino acid transferase gene in the chromosome of said recombinant Listeria , wherein said Listeria further comprises a plasmid, wherein the plasmid comprises:
a first nucleic acid sequence encoding a polypeptide, wherein said polypeptide comprises a heterologous antigen, and
a second nucleic acid sequence encoding a D-alanine racemase enzyme, wherein said plasmid does not confer antibiotic resistance upon said recombinant Listeria strain,
whereby said D-alanine racemase gene complements said mutation in said chromosome of said recombinant Listeria , wherein said plasmid is stably maintained in said recombinant Listeria strain in the absence of an antibiotic selection, and wherein said first nucleic acid sequence is operably linked to a prokaryotic promoter/regulatory sequence, wherein said administering regresses said antigen-expressing tumor or said antigen-expressing cancer in said subject.
11. The method of claim 10 , wherein said polypeptide is a fusion protein comprising said heterologous antigen and an additional polypeptide, wherein said additional polypeptide is a non-hemolytic fragment of a listeriolysin O (LLO) protein, a Proline, Glutamic acid, Serine and Threonine (PEST) amino acid sequence, or an Actin assembly inducing protein (ActA) protein or a fragment thereof.
12. The method of claim 10 , wherein said second nucleic acid sequence is operably linked to said promoter/regulatory sequence.
13. The method of claim 10 , wherein said heterologous antigen is an HPV E6 or an HPV E7 antigen.
14. The method of claim 10 , wherein said cancer is a cervical cancer.
15. The method of claim 10 , wherein said regressing said antigen-expressing tumor or said antigen-expressing cancer comprises reducing the size of a HPV antigen-expressing tumor or a HPV antigen-expressing cancer, reducing the growth rate of a HPV antigen-expressing tumor or a HPV antigen-expressing cancer, or inhibiting the growth rate of a HPV antigen-expressing tumor or a HPV antigen-expressing cancer, or any combination thereof.
16. The method of claim 15 , wherein said regressing said HPV antigen-expressing tumor or said HPV antigen-expressing cancer comprises treating said tumor or said cancer.
17. The method of claim 15 , wherein said regressing said HPV antigen-expressing tumor or said HPV antigen-expressing cancer comprises inducing an immune response against said HPV antigen-expressing tumor or said HPV antigen-expressing cancer.
18. The method of claim 17 , wherein said inducing an immune response comprises inducing HPV antigen-specific tumor-infiltrating cytotoxic T-cells (CTL).